mRNA)
搜索文档
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients
Benzinga· 2025-10-13 22:52
Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress.mRNA-4359 is an investigational immune-evasion targeted cancer antigen therapy (CAT) that encodes epitopes of two common immune escape pathways, PD-L1 and IDO1, to elicit antigen-s ...
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Accessnewswire· 2025-09-23 19:00
免疫原性数据 - 针对LP8.1变异株的中和抗体增长超过16倍 [1] - 免疫反应在12至64岁高危人群及所有65岁及以上成年人中均表现强劲 [1] 疫苗产品进展 - 2025-2026季型mNEXSPIKE疫苗取得积极的初步免疫原性数据 [1] - 数据来源于一项正在进行的第四阶段临床试验 [1]
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Globenewswire· 2025-08-28 00:50
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administrat ...
